The low participation of women in clinical trials of pharmaceuticals raises ethical issues that hinder accurate assessment of the safety and effectiveness of medicines by gender. Historically, clinical trials have been conducted primarily on men, and the thalidomide scandal further excluded women from participation. Despite policies to encourage women’s participation since 1986, women’s participation in clinical trials of pharmaceuticals remains low and needs to be improved. Given the lack of research on women’s physical characteristics and hormonal changes, increasing women’s participation in clinical trials of pharmaceuticals is essential to develop safe and effective medicines and improve public health, and improvements are needed to ensure equitable health outcomes by gender.

Ⅰ. 서 론
Ⅱ. 본 론
    1. 의약품 임상시험에서 여성 참여의 역사
    2. 의약품 임상시험에서 여성 참여의 중요성
    3. 의약품 임상시험에서 여성 참여 증진을 위한체계 마련의 필요성
Ⅲ. 결론 및 제언
참고문헌

• 김현지(이화여자대학교 간호대학) | Kim Hyun Jee (College of Nursing, Ewha Womans University)